GlassScriptPhysician profile
Virgina Sue Wright
NPI 1881070829
$16,522.87
in general payments reported to CMS, 2019-2025
34 companies · $4,166 in 2025
The $4,166 reported for 2025 was more than what 98% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,380 · 2022: $2,989 · 2023: $3,294 · 2024: $3,695 · 2025: $4,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,955.39 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,133.97 | 2021-2025 | |
| Ucb, INC. | $1,944.85 | 2021-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,767.65 | 2021-2025 | Tavneos, Enbrel, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $1,120.08 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $1,015.24 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $864.93 | 2021-2025 | |
| Glaxosmithkline, LLC. | $825.44 | 2021-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $820.37 | 2021-2025 | |
| Radius Health, INC. | $774.70 | 2021-2025 | Tymlos |
| Horizon Therapeutics Plc | $701.30 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $667.51 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $519.09 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $487.81 | 2021-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $431.66 | 2021-2025 | Orencia |
| Genentech USA, INC. | $424.26 | 2021-2025 | Actemra, Rituxan, Gazyva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $409.17 | 2021-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $377.54 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.75 | 2021-2024 | Ofev, Cyltezo |
| Organon LLC | $222.10 | 2023-2025 | Hadlima, Renflexis |
| Sobi, INC | $111.79 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.48 | 2021-2025 | Cuvitru, Hyqvia |
| Genzyme Corporation | $77.10 | 2021-2023 | |
| Axsome Therapeutics, INC. | $63.02 | 2025 | Sunosi |
| Tersera Therapeutics LLC | $60.41 | 2025 | Quzyttir |
| Janssen Scientific Affairs, LLC | $51.16 | 2022 | |
| Scilex Pharmaceuticals INC. | $33.87 | 2024 | |
| Mylan Institutional INC. | $33.65 | 2023 | Hulio |
| Biocryst US Sales Co., LLC | $27.08 | 2024 | Orladeyo |
| Sandoz INC. | $22.22 | 2023 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $17.67 | 2024 | Strensiq |
| Idorsia Pharmaceuticals US INC | $15.39 | 2023 | Quviviq |
| Biodelivery Sciences International, INC. | $14.99 | 2021 | |
| Daiichi Sankyo INC. | $14.25 | 2021 | |
| Eisai INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virgina Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.